View Press Releases
-
University of Colorado Grants License to Cirena for RNA-Synthesis Technology
Cirena has secured a license to the University of Colorado Boulder’s patented RNA synthesis technology.
Mar 10, 2026
-
Abselion Establishes US Subsidiary in Cambridge, MA
Supports closer engagement with scientists in North America, to meet growing international adoption of its Amperia protein quantification platform
Mar 9, 2026
-
Neuland to open commercial peptide facility as part of planned phased expansion
Mar 9, 2026
-
Third Annual Bio-IT World Venture, Innovation & Partnering Conference Returns to Boston May 19
Cambridge Healthtech Institute today announced the agenda for the third annual Bio-IT World Venture, Innovation & Partnering Conference, an exclusive gathering of more than 200 senior-level investors, corporate executives, entrepreneurs and startups, with a focus on connecting capital, technology, and science to accelerate drug discovery.
Mar 4, 2026
-
More Than Half of GLP-1 Users Reported Seeking Follow-Up Care for Side Effects, Phenomix Sciences Report Finds
In conjunction with Obesity Care Week, a national survey from Phenomix Sciences among medication-experienced patients found that GLP-1 outcomes, tolerability, and downstream care needs vary widely, reinforcing the need for more individualized obesity care. Real-world response varies: Many GLP-1 users reported variability in outcomes, including weight-loss plateaus, limited response, or weight gain. Care and costs often extend beyond the prescription: More than half of users required medical care to manage side effects, with some reporting significant out-of-pocket costs. One-size-fits-all falls short: The findings highlight that obesity treatment outcomes differ widely, reinforcing the need for more individualized approaches to care.
Mar 4, 2026
-
Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib
Biosimulation results highlight how model-informed approaches for drug development and regulatory decision-making save time and money.
Mar 4, 2026
-
Thermo Fisher Scientific Opens Bay Area Cryo-EM Drug Discovery Center to Accelerate Breakthrough Therapies
Thermo Fisher Scientific, the world leader in serving science, today announced the opening of its Cryo-Electron Microscopy (cryo-EM) Drug Discovery Center (CDDC) in South San Francisco. The new center provides pharmaceutical and biotechnology innovators with immersive, hands-on access to advanced cryo-EM technologies designed to accelerate structural insights and the development of life-saving therapies.
Mar 4, 2026
-
Ardena Appoints Paul Edwards as Chief People Officer
Mar 2, 2026
-
Wisdom Bioscience Establishes Scientific Advisory Board to Advance Oral Cancer Diagnostics and Screening
• Drs Giulia Kennedy, Arnold Levine, John Sninsky, Martin Goldberg and Prof Tin Tin Su join SAB • Follows close of initial funding round with investment from Stephen Quake and Jay Flatley
Mar 2, 2026
-
Camgenium Expands NHS Access to Advanced, Risk-Adjusted Clinical Audit Analytics
Mar 2, 2026
-
Proscia Earns Top Performance Score in the US, Sweeping 2026 KLAS Digital Pathology Ratings
Following Proscia’s Global Best in KLAS win in Europe, Concentriq is now the highest-rated digital pathology platform across multiple regions
Mar 1, 2026
-
START Appoints Dr. Frank Smith President of its XenoSTART Preclinical Research Business Unit
Dr. Smith will strengthen XenoSTART’s position as a premier drug development partner, translating PDX-driven insights into faster, more confident oncology development decisions.
Feb 23, 2026
-
Symbiosis Appoints Joanne Anderson as Chief Commercial Officer
Mar 1, 2026
-
Quotient Sciences Extends Commercial Manufacturing Partnership for Ultra-Rare Disease Treatment
Feb 25, 2026
-
ELRIG Appoints Dr Kelly Gray and Dr Elaine Duncan to its Board
• Strengthens leadership team to support next phase of growth as organisation evolves to meet needs of global drug discovery community • Drs Gray and Duncan to lead scientific programmes and early career initiatives, respectively
Feb 24, 2026
-
Epigenica AB Launches EpiFinder™ cNUC: The First Platform to Simultaneously Profile Multiple Histone Marks and DNA Methylation Directly from Circulating Nucleosomes in Plasma and Serum
Epigenica has announced the launch of EpiFinder™ cNUC, a unique product for liquid biopsies that significantly expands the capabilities of epigenomic research by delivering deep insights directly from circulating nucleosomes.
Feb 24, 2026
-
Healthcare Access Performance Leader BlockIt Rebrands as Alluvium Healthcare
Feb 23, 2026
-
Inceptua Group Appoints Healthcare Industry Leader Kurt Hilzinger as Chairman of the Board
Inceptua Group announces the appointment of Kurt J. Hilzinger as Chairman of the Board.
Feb 23, 2026
-
ClearNote Health’s Enhanced Avantect® Pancreatic Cancer Test Delivers Industry-Leading Early Detection Performance
ClearNote Health announced an enhanced Avantect® Pancreatic Cancer Test, which delivers a higher overall cancer detection sensitivity of 82.6% and specificity of 97.5% for patients at elevated risk of this disease.
Feb 22, 2026
-
Integrated DNA Technologies Unveils NGS Innovation Roadmap to Accelerate the Future of Cancer Research
IDT’s NGS roadmap reflects a multi-omics strategy built on differentiated chemistries and algorithms that support DNA, methylation, and RNA sequencing workflows.
Feb 22, 2026


